Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

eteplirsen Articles

Sarepta rockets as eteplirsen seen to significantly benefit Duchenne patients

4 October 2012

Sarepta's shares rocket on positive results with eteplirsen in Duchenne muscular dystrophy

25 July 2012

Showing 1-2 of 2 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS